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Abstract
The HIV care continuum is a critical framework for situational awareness of the HIV epidemic, 
yet challenges to accurate enumeration of continuum components hamper continuum estimation in 
practice. We describe local, surveillance-based estimation of the HIV continuum in the United 
States, reviewing common practices as recommended by the Centers for Disease Control and 
Prevention. Furthermore, we review some challenges and biases likely to threaten existing 
continuum estimates. Current estimates rely heavily on the use of CD4 cell count and HIV viral 
load laboratory results reported to surveillance programs as a proxy for receipt of HIV-related 
outpatient care. As such, continuum estimates are susceptible to bias due to incomplete laboratory 
reporting and imperfect sensitivity and specificity of laboratory tests as a proxy for routine HIV 
care. Migration of HIV-infected persons between jurisdictions also threatens the validity of 
continuum estimates. Data triangulation may improve but not fully alleviate biases.
Keywords
HIV Cascade; Treatment as Prevention
Introduced in 2009 to describe the HIV epidemic in Washington, DC,1 the HIV care 
cascade, now commonly called a continuum, has become a critical framework for program 
assessment.2 With guidance from the Centers for Disease Control and Prevention (CDC), 
most state and large urban health departments use routinely collected surveillance data to 
provide estimates of the number and proportion of HIV-infected persons living in their 
jurisdiction at each continuum stage. Given the variable potential for transmission by HIV-
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infected persons depending on their position in (or outside of) the continuum, this 
framework is appealing.3
The most common presentation of the continuum is a series of vertical bars representing the 
proportion of HIV infected persons in a particular area who have been diagnosed, ever 
linked to HIV care, who are currently retained in care, and who are virally suppressed. For 
examples of the use of the HIV continuum, we refer the reader to Greenberg (2009),1 
Gardner (2011)4 and Cohen (2014).5 Although seemingly intuitive, in practice the HIV 
continuum is difficult to estimate accurately. In the United States (US), estimates are 
typically based on surveillance data that are often incomplete. However, despite such 
limitations, public health agencies rely on the continuum estimates to plan and respond to 
the HIV epidemic. In this paper, we first describe local (i.e., state or Metropolitan Statistical 
Area) estimation of the HIV continuum using surveillance data, reviewing common 
practices. Subsequently, we review challenges and biases likely to threaten existing 
continuum estimates, and we provide suggestions for improvement. We use examples from 
North Carolina’s (NC) continuum estimation efforts to illustrate our points.
METHODS
We interviewed public health practitioners and epidemiologists responsible for HIV 
surveillance and programmatic activities at the NC Division of Public Health to gain 
understanding about local continuum estimation practices and relevant surveillance data. We 
also reviewed programmatic guidance and HIV continuum estimates from other jurisdictions 
published in the scientific literature and on state health department websites. Finally, we 
conducted simple analyses of NC surveillance data to illustrate the existence and magnitude 
of potential biases in continuum estimation.
CURRENT ESTIMATION PRACTICES
Data sources
All 50 states, the District of Columbia, and US dependent areas collect reports of new HIV 
and AIDS diagnoses made by physicians, hospitals and laboratories in their jurisdictions and 
store these data in the enhanced HIV/AIDS Reporting System (eHARS).6 These surveillance 
data are used in the estimation of every stage of the HIV continuum (including the total 
number of infected persons, diagnosed and undiagnosed, in at least some settings). 
Increasingly, states have updated reporting rules to also mandate laboratory reporting of 
CD4 cell count and HIV RNA viral load results.7. Public health agencies participating in the 
Routine Interstate Duplicate Review (RIDR) forward HIV and AIDS case reports to CDC 
with the date of HIV or AIDS diagnosis, Soundex name-based code, birth date, and sex at 
birth, which CDC uses to compare to previously reported cases and identify possible 
duplicate cases (persons who have previously been HIV-diagnosed in another jurisdiction). 
CDC alerts the agencies of possible duplicates and the agencies resolve them using 
identifiable information.8 Other data sources, including the Medical Monitoring Project, 
Medicaid and Medicare billing data, and Ryan White Program data (e.g. AIDS Drug 
Assistance Program and CAREWare) can provide supplemental information about the HIV 
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continuum, but are not necessarily available in all jurisdictions. Brief descriptions of these 
data sources are available in table 1.
HIV prevalence
The CDC uses back-calculation methods to estimate the number of HIV-infected persons 
living in the US, which is then used as the denominator of national continuum estimates.9 
CDC recommends jurisdictions skip reporting overall prevalence, and use HIV-diagnosed 
persons as the denominator when producing local continuum estimates. CDC releases 
incidence estimates (linked to undiagnosed prevalence) for states that contribute sufficient 
serologic data (at least 15% completeness of Serologic Testing Algorithm for Recent HIV 
Seroconversion [STARHS] results); these estimates are based on the same back-calculation 
approach used for national incidence and prevalence estimation. NC is one such state and 
briefly used those state-specific estimates to scale their number of reported HIV cases to 
estimate local HIV prevalence.
HIV diagnosis
To estimate proportions of HIV-diagnosed persons at each stage of the continuum (except 
linked to care) CDC recommends defining the HIV-diagnosed population (the denominator 
for those proportions) as persons who are alive, HIV-diagnosed for at least 12 months by the 
date of analysis and thought to be residing in the jurisdiction based on last known address. 
This estimate excludes persons who die within a year of their HIV diagnosis and persons 
who were diagnosed in the jurisdiction but are known to have then emigrated. It includes 
persons diagnosed in another jurisdiction who are known to have immigrated. Only persons 
newly diagnosed within the jurisdiction (excluding persons previously diagnosed in another 
jurisdiction) during a given period are included in the denominator when estimating the 
proportion of HIV-diagnosed persons linked to care.
Linkage to HIV care
Linkage to care is estimated using reported CD4 cell count or viral load results as a proxy 
for receipt of HIV-related outpatient medical care (where such laboratory data are reported 
to surveillance). Linkage to care is defined in this context as having had a least one HIV-
related medical care visit within 3 months of HIV diagnosis,9–11 and CDC recommends 
jurisdictions operationalize this definition by calculating the proportion of patients 
diagnosed within a given year who have at least one CD4 cell count or viral load 
measurement within 3 months of HIV diagnosis. Another family of measures has been used 
to identify patients whose linkage to care is more stable, although such measures are not 
included in the CDC guidance. These measures are typically operationalized as having had 
at least two laboratory results within some short interval following HIV diagnosis.12
Retention in HIV care
Surveillance-based metrics for measuring retention in care again rely on the use of routinely 
reported laboratory results (where available) as a proxy for an HIV-related medical visit. 
The CDC has endorsed the National HIV/AIDS Strategy (NHAS) metric of two or more 
routine HIV-related medical visits at least three months apart within a calendar year2 (where 
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laboratory test results are substituted for visits in the CDC guidance). The U.S. Department 
of Health and Human Services and the Health Resources and Services Administration, HIV/
AIDS Bureau, use a different definition of at least one routine medical visit during each 6-
month period over a 24-month observation period, with a minimum of 60 days between the 
first visit in one period and the last visit in a subsequent period.10,11,13
States participating in the Medical Monitoring Project (MMP), a CDC-funded initiative to 
monitor HIV patients who are in care,14 also have the option of using weighted MMP data 
to estimate retention in care. The number of patients in the MMP known to have had at least 
one medical visit from January through April of the MMP surveillance year (the Population 
Definition Period) is weighted by the probability of MMP sample selection, adjusted for 
nonresponse, to get a population estimate of the number of HIV-infected adults who 
attended at least one medical visit during the same period.9
Viral suppression
The proportion of people living with HIV with suppressed viral load is most commonly 
based on the number of patients whose most recently reported viral load test within a 
specified period of time was below the limit of detection,12 which is commonly, although 
not universally, set at <200 copies/mL (also the CDC recommended threshold).11,15 States 
participating in the MMP can also estimate the proportion of patients in care whose most 
recent viral load was below the limit of detection.
LIMITATIONS OF CURRENT ESTIMATION APPROACHES AND 
SUGGESTIONS FOR IMPROVEMENT
While each stage of the continuum presents unique challenges for estimation, common 
threats to surveillance-based estimation of all stages (beyond diagnosis) include reliance on 
laboratory reporting of CD4 cell count and viral load results to public health agencies, and 
potential for bias due to missing data. The completeness of laboratory reporting is 
heterogeneous across jurisdictions16,17 and is changing rapidly over time due to changing 
reporting rules and the adoption and implementation of electronic laboratory reporting. The 
completeness of laboratory reporting can dramatically alter estimates of the HIV continuum.
Continuum estimates vary considerably across jurisdictions, even among those that claim to 
have laboratory reporting compliance ≥95%.11 While access to and retention in HIV care are 
likely to truly differ, some variation is undoubtedly artifactual, arising from differences in 
data collection procedures and reporting completeness. CDC does not recommend 
jurisdictions attempt local estimation of the care continuum until over 95% of laboratory 
results are reported. However, estimating the total number of expected results and 
completeness of reporting is not straightforward. Even in states where laboratory reporting is 
mandated, some laboratories may lack the time or technological capacity to comply with the 
reporting rule. Furthermore, internal and external stakeholders may press for continuum 
estimates despite data quality issues. Interpretation of individual continuum estimates and 
comparisons of estimates across jurisdictions would greatly benefit from clear disclosure of 
data quality and completeness, as well as reporting of methods used to calculate 
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completeness. With such information, bounds of continuum estimates given the missing data 
are easily calculated and reported. Limitations and suggestions related to stage-specific 
continuum estimates are outlined below.
HIV prevalence
Currently, jurisdictions are discouraged from starting their HIV continuum with the number 
of HIV-infected persons, which limits comparisons of HIV continua across jurisdictions. If 
local jurisdictions are able to collect and submit sufficient serum samples and data to get 
local prevalence estimates using the STARHS algorithm, or other algorithms for recency 
testing, differences in the prevalence of HIV and the proportion of HIV-infected persons 
who are undiagnosed would be illustrative regarding the penetration of HIV testing locally. 
The use of the BED assay and back-calculation approach currently relied on to estimate HIV 
incidence may not perform uniformly across place and time18,19 and improvements on the 
algorithm are possible.20 Regardless of the specific method used to estimate HIV 
prevalence, however, bounds representing the uncertainty in that estimate should be 
presented, and carried forward through all future stages of the continuum.
HIV diagnosis
Several biases threaten the accuracy of estimates of the number of HIV-diagnosed persons 
living in a jurisdiction. First, full enumeration of HIV diagnoses (whether new diagnoses or 
the first diagnosis for an HIV-infected person after immigrating to a new jurisdiction) 
depends on the level of resources allocated to active surveillance, providers’ knowledge of 
their legal obligation to report, completeness of laboratory reporting (enhanced by the 
adoption of automated electronic laboratory reporting), and the accuracy of the information 
contained in the final case report. Around 2003, CDC estimated that nationally, 
completeness of case ascertainment was between 72% and 95%.21 In 2012, NC estimated 
that statewide, case ascertainment was between 90% and 95% complete.22
Second, estimates of the number of HIV-diagnosed persons living in a jurisdiction may be 
biased by unrecognized migration into and out of the jurisdiction. For an HIV-positive 
migrant to be properly accounted for by surveillance, the case must: 1) interact with the 
healthcare system and have their HIV infection recognized; 2) be reported in the new state 
(some providers do not recognize their obligation to report HIV infection in a person who is 
not newly diagnosed); and 3) be identified as a duplicate (already reported to CDC by 
another state) by the RIDR matching algorithm. Emigration from a jurisdiction that goes 
unrecognized results in overestimation of HIV-infected persons in the old jurisdiction and 
underestimation of HIV-infected persons in the new jurisdiction. If the case is identified as 
HIV-positive in the new jurisdiction but not recognized as a duplicate, the number of HIV-
infected persons is only overestimated in the old jurisdiction. Given these challenges to 
migrant recognition and de-duplication, as well as high rates of migration between counties 
and states,23 local estimates of the number of HIV diagnosed people living in a given 
jurisdiction are likely inaccurate, with subsequent effects on “downstream” cascade stage 
estimates. For example, in King County, WA, 16% of persons presumed to be living with 
HIV in the county over a 4-year period were found to have emigrated, and accounting for 
emigration reduced the estimated proportion of patients out of care from 27% to 16%.24 
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Services like Accurint (http://www.accurint.com/) reduce (but do not eliminate) the 
resources required for such case investigation. If case investigation of persons not known to 
be in care is not feasible, at the very least, immigration and emigration rates as detected 
through the RIDR process should be reported across time to monitor migration trends. 
Furthermore, sensitivity analyses based on different assumptions about the proportion of 
chronically out-of-care patients who have actually emigrated would be informative as to the 
potential impact of migration on continuum estimates.
Other potential biases are inherent in the denominator for estimation of subsequent stages of 
the continuum. Because patients are required to survive at least 1 year after diagnosis before 
they are included in continuum denominators for retention and viral suppression, patients 
who are diagnosed with advanced disease may be underrepresented. Jurisdictions with 
different 1-year survival rates will not be comparable, and jurisdictions will not be 
comparable to themselves across time if 1-year survival rates change. If the current 
continuum estimation framework is used, jurisdictions should report 1-year survival rates in 
conjunction with continuum estimates. Alternatively, continuum estimation could embrace a 
competing risk framework to incorporate early deaths more intuitively.25
Linkage to HIV care
Laboratory under-reporting issues aside, laboratory results are a sub-optimal proxy for 
receipt of routine HIV-related medical care, the actual indicator of interest for care 
attendance in the major recommendations and guidelines. Not all CD4/VL testing is 
associated with receipt of routine HIV care (e.g., CD4/VL testing on inpatients or during 
emergency department visits). Furthermore, laboratory testing proximal to HIV diagnosis 
might be associated with diagnosis and not with initiation of medical care.26 Some 
jurisdictions have excluded laboratory results collected within a short time of HIV diagnosis 
(e.g., 30 days) when estimating linkage to care,27 which may reduce the number of patients 
classified as linked who did not initiate care, but increase the number of patients classified 
as not linked who did.
While CDC recommends measuring linkage to care based on 1 visit after diagnosis, it is not 
yet clear that this measure is of greater public health importance than a metric based on 2 
visits. The two metrics often yield markedly different results. In King County, WA, 90% of 
people diagnosed between 2007 and 2009 had one laboratory measurement within 3 months, 
but only 73% had a second reported 3–9 months after diagnosis.26 We believe that both 
metrics provide valuable information, and where they differ, jurisdictions should focus on 
understanding barriers to attending a second visit, and on modifying the first clinical care 
visit to promote better engagement and retention.
Retention in HIV care
Data triangulation can help identify biases and improve continuum estimates, particularly 
estimates of retention in care.28 We compared NC estimates of retention based on laboratory 
results reported to eHARS only (standard estimates) with results based on triangulating data 
from eHARS, Medicaid, Medicare, CAREWare and ADAP. The latter databases capture 
encounters with medical providers and pharmacies, in addition to laboratory data. Using 
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data triangulation, 77% of HIV-diagnosed North Carolinians were classified as retained in 
care in 2010. However, only 44% of HIV-diagnosed persons were classified as retained in 
care using eHARS data alone.29
While improvements are possible with data triangulation, however, the availability of 
external data sources varies across jurisdictions and those sources commonly available often 
miss patients with private insurance and patients who seek HIV care outside the jurisdiction 
(i.e., across state or county lines). This is of concern to NC for patients in the Charlotte area, 
who may seek care across state lines in South Carolina. Furthermore, as HIV treatment has 
become more effective and less toxic, some physicians have reduced the frequency of 
laboratory monitoring,15,30,31 potentially leading to misclassification of retained patients as 
not retained in care.
MMP is considered one of the best sources of estimates of HIV care in the US,32 but the 
validity of estimates of retention in care depends upon the representativeness of the sample. 
In NC in 2009, the facility-level response rate was only 77% and the adjusted patient-level 
response rate was 51%.9 Participants in the MMP are more likely to be from larger clinics 
(that have the resources to agree to participate if sampled) and to be frequent users of 
services (higher probability of having a visit in the population definition period). The next 
round of MMP will sample patients directly (rather than sampling clinics first), which may 
reduce, but not eliminate, this potential for selection bias. Methods exist for evaluating33,34 
and adjusting for35 selection bias and should be utilized to address estimation of retention in 
care and characterization of the in-care population.
Finally, while this stage is labeled retention in care, a state of being that is dynamic (unlike 
diagnosed or linked to care, in which a person only changes states once, i.e., once diagnosed, 
no one can return to being undiagnosed), the commonly used metrics only capture a static 
snapshot of the proportion of persons who received care within a set period. Comparisons of 
the proportion retained in care in one year versus the next does not say anything about how 
often individuals transition between being in care versus out of care, nor the proportion of 
persons transitioning between these two states. Because current metrics do not capture 
transitions directly, they are insufficient for evaluating the effect on the continuum of 
interventions focused on re-engaging persons in care. Additional HIV continuum metrics 
should estimate progress through the HIV continuum in addition to the current status of 
HIV-infected persons. The development of complementary frameworks and approaches is 
an active area of research, and several have been recently proposed.36–38
Viral suppression
Estimation of viral suppression is limited by the lack of a consensus definition and 
laboratory reporting. The threshold used to define viral suppression for reporting and for 
surveillance definitions can have a dramatic impact on estimates.39 Viral suppression, like 
retention in care, is dynamic and information is lost when it is summarized with only a 
cross-sectional snapshot, as in the continuum framework. Detectable viral load results may 
reflect chronic non-suppression, true viral failure or simply a detectable “blip”.40 In British 
Columbia, 66% of diagnosed patients were classified as virally suppressed based on one 
undetectable viral load measurement in a given year, compared to 53% classified as virally 
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suppressed based on at least 2 undetectable viral load measurements at least 3 months 
apart.39 We recommend a more nuanced treatment of viral suppression, and suggest that, as 
with “retention in care” process is as important as current status; categorizing patients based 
on a cross-tabulation of ever suppressed and suppressed at the time of the most recent 
measurement would highlight whether persons classified as having unsuppressed viral load 
were never treated or rather in need of adherence counseling. The complementary 
frameworks mentioned in the prior section are relevant here, too.36–38
CONCLUSIONS
Estimation of the HIV continuum could be improved with careful consideration of several 
key issues. Triangulation of data sources (including possible data sharing across 
jurisdictions and through public-private partnerships) and sensitivity analyses with these 
considerations in mind are likely to result in a more nuanced understanding of each 
continuum stage. Quantifying the uncertainty of surveillance estimates, including providing 
a range of estimates for each stage (e.g., based on results from different sources, varying 
assumptions about data completeness, or different definitions of “retained” or “virally 
suppressed”), rather than an artificially precise, single numerical estimate, is informative and 
should be encouraged, rather than avoided.41 As data completeness improves, the 
proportions linked and retained in care calculated using the proxy of a reported laboratory 
value are likely to increase. Strategies to quantify improvements in cascade outcomes due to 
improved data quality – and to distinguish these artifactual improvements from true 
improvements – are needed to ensure scarce public health resources are maximally 
leveraged. Finally, published continuum estimates should include a detailed description of 
data collection procedures, data quality, definitions used, and analysis decisions made.
The HIV care continuum is a critical tool for conceptualizing and monitoring the HIV 
epidemic in the United States and globally. However, the challenges to its accurate 
enumeration are often given insufficient attention. Given the importance of the continuum in 
monitoring and evaluating our efforts to control the epidemic and improve the lives of 
people living with HIV, considerable efforts should be devoted to improving its accuracy 
and utility. We applaud the work of public health in transforming the paradigms under 
which HIV surveillance has been done and we encourage public health practitioners to 
publish their work and further suggestions for and experiences with continuum estimation, 
which could be aggregated to establish a new standard for estimation.
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Table 1
Brief description of databases relevant for HIV care continuum estimation in NC and in other jurisdictions
Database Descriptiona
ADAP AIDS Drug Assistance Program; database includes all HIV-positive persons who have applied for ADAP funding, including 
data on HIV medication utilization for persons having drugs paid for by ADAP.
CAREWare Database includes all HIV positive persons who received services paid for by Ryan White Part B funds, including the dates and 
types of services provided.
eHARS Enhanced HIV/AIDS Reporting System; database includes all persons diagnosed with HIV or AIDS or living with HIV/AIDS in 
NC who have been reported to the NC Division of Public Health.
MMP Medical Monitoring Project; database include clinical and interview data on a representative sample of all HIV positive persons 
who are in medical care in NC.
a
More detailed descriptions of these, and all databases relevant for HIV surveillance and care continuum estimation are available in the appendix 
of the NC Epi Profile: http://epi.publichealth.nc.gov/cd/stds/figures.html#profile
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